Merck tops third-quarter estimates as Keytruda, Gardasil outperform
Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for its blockbuster cancer drug Keytruda and its HPV vaccine Gardasil.
Merck posted higher-than-expected third-quarter earnings on Thursday, driven by strong demand for its blockbuster cancer drug Keytruda and its HPV vaccine Gardasil.